| NCT ID | NCT05373043 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Long-COVID |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-11-01 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2022-11-01 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function and minimize the long-term consequences of COVID-19.
Eligibility Criteria
Inclusion Criteria: * 50 years of age or greater * Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis * Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis * Ability to sign informed consent Exclusion Criteria: * BMI \>45 kg/m2 * Unstable (\<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index \<0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (\>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance \<30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia * Orthopedic limitations that would prohibit exercise * \[Current smokers and individuals that stopped smoking in the last 10 years\] * Already taking Mito-Q or unwilling to cease dietary supplements for participation * Any other condition or event considered exclusionary by the PIs or a physician
Contact & Investigator
Joel Douglas Trinity, PhD
PRINCIPAL INVESTIGATOR
VA Salt Lake City Health Care System, Salt Lake City, UT
Frequently Asked Questions
Who can join the NCT05373043 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Long-COVID. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05373043 currently recruiting?
Yes, NCT05373043 is actively recruiting participants. Contact the research team at Joel.Trinity@va.gov for enrollment information.
Where is the NCT05373043 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT05373043 clinical trial?
NCT05373043 is sponsored by VA Office of Research and Development. The principal investigator is Joel Douglas Trinity, PhD at VA Salt Lake City Health Care System, Salt Lake City, UT. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.